Bristol Myers Squibb has opened its radiopharmaceutical manufacturing facility in Indianapolis, which played a major role in ...

The Bristol Myers Squibb subsidiary RayzeBio has opened a new 77,000-square-foot facility in Indianapolis, Indiana.

Bristol Myers Squibb is preparing to ship a new and possibly life-changing cancer treatment to patients across the world. The ...

RayzeBio’s IPO will support pivotal testing of a targeted radiopharmaceutical for cancer patients who progress after treatment with Novartis’s Lutathera. Neumora will apply its IPO cash toward ...

Radiopharmaceutical drugmaker RayzeBio drew interest from two other large drugmakers before agreeing to a $4.1 billion buyout by Bristol Myers Squibb, newly published documents show.

Initiating RayzeBio, Inc. coverage with a Buy rating and common stock price target of $43 based on my risk-adjusted NPV discounted cash flow model, representing a 110% upside. The company's ...

RayzeBio is a recent IPO and a late-stage developer of radiotherapeutic product candidates targeting various cancers. Find out my analysis of RYZB stock.

RayzeBio believes its strategic investments in building a robust product pipeline, development capabilities, and manufacturing infrastructure position the company to be an industry-leading pioneer ...

RayzeBio's $4.1 billion deal to be acquired by Bristol Myers caps a brief but lucrative run as a public company for the radiopharmaceutical firm. RayzeBio went public in September at $18 a share ...

Three biotech VC veterans, including one of the co-founders of radiopharma success story RayzeBio, are launching a new investment fund called Scion Life Sciences.

After leading his previous company through a back-to-back IPO and M&A deal, the former chief executive of RayzeBio has raised $370 million to develop ...